Warhound Unveiled With $200M to Create Engineered K9s for Military

A billion-dollar bet on synthetic biology has officially left the shadows with the launch of Warhound, a venture designed to genetically engineer the next generation of military working dogs.

The startup announced on Thursday that it has secured $200 million in funding from a group of investors that includes Sequoia, 8VC, Corner Ventures, and In-Q-Tel. The latter is a venture firm supported by the CIA and other U.S. intelligence agencies. This capital injection values the company at $1.2 billion. The firm was co-conceptualized by Ben Lamm of Colossal Biosciences and Anduril co-founder Palmer Luckey, who first discussed the idea at a conference roughly a year ago.

The core problem Warhound seeks to solve is a shrinking domestic supply of qualified working dogs. Currently, over 80 percent of the U.S. military’s canine units originate from Europe. Furthermore, fewer than half of those imported dogs are deemed fit for service. Lamm noted that many dogs fail training due to inherited issues such as poor eyesight, hip dysplasia, muscle atrophy, or a high propensity for cancer. The new venture intends to change this reliance on foreign sources by creating a new type of dog with characteristics suited for demanding missions.

The engineering process involves taking cell lines from top-performing breeds, specifically the Belgian Malinois and German Shepherd. These cells are placed in a biobank where the team will edit their genes. The goal is to add traits that improve speed, agility, and olfactory sensors for bomb sniffing, while removing genes that contribute to health problems. Colossal Biosciences will license its technology to support this effort, leveraging its existing work in gene cloning and de-extinction projects.

Anduril plays a critical hardware role in the operation. The company will provide software and gear, including protective vests and goggles, to enhance situational awareness for both the dogs and their handlers. Lamm described the concept as adding technology on top of the dog rather than inside it. For instance, bulletproof vests could contain data sensors that transmit information back to handlers, allowing them to better understand the tactical environment. This approach aims to make the dogs safer and healthier while also protecting the human personnel working alongside them.

Luckey is a partner in the venture but holds no equity, according to Lamm. Colossal owns a stake in the business. The cloning process will be handled by Viagen, another company owned by Colossal, which has a high success rate in cloning technology already used for endangered species. Lamm stated that the first batch of dogs is about to be cloned and incubated, with births expected in early 2027. The company hopes these dogs will begin service within two years.

Warhound has not yet disclosed pricing, but it plans to sell to the Department of Defense, military service groups, police forces, and first responders. Lamm said the company has briefed numerous government groups on the business. To address concerns about animal welfare, the company is working under the guidance of the American Humane Society to certify its training program. The organization said it applauds the collaboration and looks forward to ensuring the animals are treated humanely. Retired dogs from this program could also enter the Society’s Military Working Dog Reunification Program to find new homes.

The next steps for Warhound involve the immediate cloning and incubation of the initial cohort. The company expects to see the first pups born in the early part of next year. If the timeline holds, these genetically enhanced and technologically equipped dogs could enter active service in as little as two years, marking a significant shift in how the U.S. military procures and maintains its working dog units.